Overview
Israel has no peptide-specific statute; peptides that are intended for human therapeutic use are treated as medicinal preparations under the Pharmacists Ordinance and its Preparations Regulations, which bar manufacturing, marketing or prescribing any preparation that is not registered with the Ministry of Health. Registered peptide drugs (such as the semaglutide products Ozempic and Wegovy) are prescription-only and have been the subject of direct Ministry of Health dispensing directives, while unregistered 'research' peptides like BPC-157 or TB-500 have no lawful commercial route to the Israeli market. Selling or distributing unregistered performance-enhancing preparations is a criminal offence enforced by the Ministry of Health's enforcement division together with police and customs, although personal use and possession are not themselves criminalised. Personal importation of an unregistered medicinal product requires an advance permit from the Ministry of Health rather than being freely allowed.
Key Points
- Under section 47A of the Israeli Pharmacists Ordinance, no person may produce, market or prescribe a pharmaceutical preparation unless it is registered, which is the provision the Ministry of Health invoked when it ordered pharmacists to stop selling Ozempic for weight loss. [2]
- Israeli pharmaceutical law is built around a registration requirement with narrow exemptions, including products imported in non-commercial amounts for personal use and preparations compounded by a pharmacist for an individual patient on a doctor's instruction, and the country's controlled-substance list sits separately in the Controlled/Dangerous Drugs Ordinance of 1973. [1]
- The Dangerous Drugs Ordinance (New Version 5732–1973) is the instrument that defines Israeli drug offences — possession, trafficking, import and export — and sets their maximum sentences, and it is the vehicle used to schedule new psychoactive substances. [5]
- The sale and distribution of performance-enhancing substances (the category into which growth-hormone and related peptide products fall in Israeli enforcement practice) are criminal offences under the Israeli pharmacy ordinance, while personal use and possession are not criminalised. [4]
- Enforcement is carried out by the Ministry of Health's Division of Enforcement and Inspection in cooperation with the Israel Police and customs agents, chiefly through seizures at suspicious sites. [4]
- In 2024 the Ministry of Health issued a directive ending off-label prescribing of the semaglutide product Ozempic for weight loss once the registered weight-loss product Wegovy became available in Israel, confirming that semaglutide-class peptides are prescription medicines controlled through the registration and labelling system. [3]
- Importing an unregistered medicinal product into Israel requires applying to the Ministry of Health for an import permit rather than relying on any automatic personal-import allowance. [6]
- No Israeli Ministry of Health guidance, scheduling entry, or enforcement action naming BPC-157 or TB-500 specifically was located in this research; the classification above is inferred from Israel's general registration and prescription rules for medicinal preparations rather than from a peptide-specific Israeli source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)